Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02926690 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
A Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by OncoTherapy Science.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT02926690 is a Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by OncoTherapy Science. The registered enrollment target is 70 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT02926690, a Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by OncoTherapy Science.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG OTS167PO
Study Locations (8)
New York
- Weill Cornell Medicine | NewYork-Presbyterian - New York
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- Norwalk Hospital - Norwalk
Georgia
- Emory University, Winship Cancer Institute - Atlanta
Hawaii
- Kapi'olani Medical Center for Women & Children - Honolulu
New Hampshire
- Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center - Lebanon
Texas
- MD Anderson Cancer Center - Houston
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-05-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02926690
The ClinicalTrials.gov registry entry for NCT02926690 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoTherapy Science, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which OTS167PO is the first listed.
NCT02926690 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT02926690 about?
NCT02926690 is a clinical study titled "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer". The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
What is the current status of trial NCT02926690?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2017-05-29. Estimated completion is 2027-09.
What conditions does trial NCT02926690 study?
This clinical trial studies the following conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02926690?
The interventions under investigation include: OTS167PO (DRUG).
Who is sponsoring clinical trial NCT02926690?
This trial is sponsored by OncoTherapy Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02926690 being conducted?
This trial has 8 study locations across Connecticut, Georgia, Hawaii, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.